CGEM MarketBeat 2 days ago Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
CGEM PR Newswire 5 days ago CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight 📈 AI Sentiment Highly Positive 9/10
CGEM MT Newswires 6 days ago Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday ➖ AI Sentiment Neutral 5/10
CGEM MT Newswires 6 days ago Wedbush Adjusts Price Target on Cullinan Therapeutics to $36 From $34, Maintains Outperform Rating 📈 AI Sentiment Highly Positive 8/10
CGEM GlobeNewswire 6 days ago Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results